Clone:
REA250
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC
Alternative names:
MPL, C-MPL, MPLV, THCYT2, TPOR

Extended validation for CD110 Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA250
1.6.1++
A16017A-
A16017E-
1.78.1-
Cells were incubated with an excess of purified unconjugated CD110 (REA250) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones forCD110. Human platelets cells were stained with CD110 antibodies and with a suitable counterstaining. As a control, CD110 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones forCD110. Human platelets cells were stained with CD110 antibodies and with a suitable counterstaining. As a control, CD110 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones forCD110. Human platelets cells were stained with CD110 antibodies and with a suitable counterstaining. As a control, CD110 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones forCD110. Human platelets cells were stained with CD110 antibodies and with a suitable counterstaining. As a control, CD110 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones forCD110. Human platelets cells were stained with CD110 antibodies and with a suitable counterstaining. As a control, CD110 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones forCD110. Human platelets cells were stained with CD110 antibodies and with a suitable counterstaining. As a control, CD110 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD110 (REA250). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD110 (REA250). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD110 (REA250). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD110 Antibody, anti-human, REAfinity™

Overview

Clone REA250 recognizes the CD110 antigen, a type I transmembrane protein and a member of the hematopoietin receptor family, which is also known as myeloproliferative leukemia protein (MPL) or thrombopoietin receptor (TPO-R). CD110 is expressed on hematopoietic stem cells, a subfraction of hematopoietic precursor cells, cells of the megakaryocytic lineage, and platelets. It serves as a receptor for thrombopoietin and CD110 deficiency leads to severe thrombocytopenia, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation.
Additional information: Clone REA250 displays negligible binding to Fc receptors.

Alternative names

MPL, C-MPL, MPLV, THCYT2, TPOR

Detailed product information

Technical specifications

CloneREA250
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD110
Alternative names of antigenMPL, C-MPL, MPLV, THCYT2, TPOR
Distribution of antigenmegakaryocytes, platelets
RRIDAB_2654527, AB_2654528, AB_2654529, AB_2654530, AB_2654531, AB_2654532

Resources for CD110 Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD110 Antibody, anti-human, REAfinity™

Publications

  1. Vigon, I. et al. (1992) Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc. Natl. Acad. Sci. U.S.A. 89: 5640 -5644
  2. Chou, F. S. et al. (2011) The thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis. J. Cell. Biochem. 112(6): 1491-1498
  3. Kaushansky, K. et al. (1998) The role of the MPL receptor in myeloproliferative disorders. Leukemia 12: S47-S50

Related products for
CD110 Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?